NCT00826644 (COMBAT) is a Phase 3 clinical trial of Belotecan in Carcinoma, Small Cell, sponsored by Chonnam National University Hospital.

Who is sponsoring NCT00826644?

NCT00826644 is sponsored by Chonnam National University Hospital.

What drugs are being tested in NCT00826644?

Interventions in NCT00826644: Belotecan, Etoposide, Cisplatin.

What condition does NCT00826644 study?

NCT00826644 studies Carcinoma, Small Cell.

Is NCT00826644 still recruiting?

NCT00826644 is currently completed. Last updated 2 August 2021.

Last reviewed 2021-08-02 · How we verify

NCT00826644: COMBAT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Randomized Prospective Multicenter Trial of Belotecan/Cisplatin Versus Etoposide/Cisplatin in Patients With Previously Untreated, Extensive-stage Small-cell Lung Cancer

Completed Phase 3 Last updated 2 August 2021

What this trial tests

Phase 3 trial testing Belotecan in Carcinoma, Small Cell in 147 participants. Completed in 1 February 2013.

Timeline

1 January 2009

Primary endpoint
1 February 2013

1 February 2013

Quick facts

Lead sponsor	Chonnam National University Hospital
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	147
Start date	1 January 2009
Primary completion	1 February 2013
Estimated completion	1 February 2013
Sites	1 location across South Korea

Drugs / interventions tested

Belotecan (BELOTECAN) — full drug profile →
Etoposide (etoposide) — full drug profile →
Cisplatin (cisplatin) — full drug profile →

Conditions studied

Carcinoma, Small Cell — all drugs for Carcinoma, Small Cell →

Sponsor

Chonnam National University Hospital

Who can join

Adults 19 to 80, any sex, with Carcinoma, Small Cell. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

To assess the response Rate of Belotecan/Cisplatin versus Etoposide/Cisplatin in patients with previously untreated, extensive-stage small cell lung cancer
Time frame: two years

Sponsor's own description

Belotecan (Camtobell, CKD-602, Chong Kun Dang Pharm., Korea) is a new camptothecin derivative, that exhibits anticancer effects by inhibiting topoisomerase I. The investigators will have a randomized prospective multicenter trial of Belotecan/Cisplatin versus Etoposide/Cisplatin in patients with previously untreated, extensive-stage small cell lung cancer. Primary endpoints * to assess Response Rate Secondary endpoints * to assess Overall response duration, Time to progression, Overall survival

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

A novel mutation panel for predicting etoposide resistance in small-cell lung cancer.
Qiu Z, Lin A, Li K, Lin W, et al · · 2019 · cited 45× · PMID 31417239 · DOI 10.2147/dddt.s205633
Belotecan/cisplatin versus etoposide/cisplatin in previously untreated patients with extensive-stage small cell lung carcinoma: a multi-center randomized phase III trial.
Oh IJ, Kim KS, Park CK, Kim YC, et al · · 2016 · cited 13× · PMID 27566413 · DOI 10.1186/s12885-016-2741-z

Verify or expand the search:

Other recruiting trials for Carcinoma, Small Cell

Currently open trials in the same condition.

NCT04660929 — CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors · Phase 1 · active not recruiting

Other Chonnam National University Hospital trials

Trials by the same sponsor.

NCT07390461 — Effectiveness of Artificial Intelligence Integrated Mixed Reality-based High-Alert Medications Management Simulation Pro · NA · not yet recruiting
NCT07482228 — Long-term Clinical Outcomes After Retinal Artery Occlusion · recruiting
NCT06954714 — Late-lumen Changes After Drug-Coated Balloon Angioplasty Versus Drug-Eluting Stents in De Novo Coronary Lesions · NA · recruiting
NCT07002164 — Timing of Coronary Angiography in NSTEMI Complicated by Acute HF · NA · recruiting
NCT06227754 — OCT Versus Angiography for Culprit Lesion Revascularization in Acute Myocardial Infarction PatiEnts · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00826644 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chonnam National University Hospital
Last refreshed: 2 August 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00826644.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing